Education
About Us
Working with TipRanks
Follow Us
Serina Therapeutics (SER)
:SER
Total Valuation
Serina Therapeutics has a market cap or net worth of $54.53M. The enterprise value is $60.73M.
Market Cap$54.53M
Enterprise Value$60.73M
Share Statistics
Serina Therapeutics has 10,250,588 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding10,250,588
Owned by Insiders62.93%
Owned by Institutions1.66%
Financial Efficiency
Serina Therapeutics’s return on equity (ROE) is -17.38 and return on invested capital (ROIC) is -391.19%.
Return on Equity (ROE)-17.38
Return on Assets (ROA)-1.66
Return on Invested Capital (ROIC)-391.19%
Return on Capital Employed (ROCE)-3.91
Revenue Per Employee4.67K
Profits Per Employee-933.92K
Employee Count12
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Serina Therapeutics is ―. Serina Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value57.52
Price to FCF―
Price to Operating Cash Flow-3.43
PEG Ratio―
Income Statement
In the last 12 months, Serina Therapeutics had revenue of 56.00K and earned -11.14M in profits. Earnings per share was -1.51.
Revenue56.00K
Gross Profit-138.00K
Operating Income-17.05M
Pretax Income-11.14M
Net Income-11.14M
EBITDA-10.49M
Earnings Per Share (EPS)-1.51
Cash Flow
In the last 12 months, operating cash flow was -15.62M and capital expenditures -8.00K, giving a free cash flow of -15.63M billion.
Operating Cash Flow-15.62M
Free Cash Flow-15.63M
Free Cash Flow per Share-1.52
Dividends & Yields
Serina Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.73
52-Week Price Change-32.57%
50-Day Moving Average5.51
200-Day Moving Average5.25
Relative Strength Index (RSI)48.72
Average Volume (3m)225.34K
Important Dates
Serina Therapeutics upcoming earnings date is Nov 18, 2025, After Close (Confirmed).
Last Earnings DateAug 11, 2025
Next Earnings DateNov 18, 2025
Ex-Dividend Date―
Financial Position
Serina Therapeutics as a current ratio of 2.40, with Debt / Equity ratio of 10.27%
Current Ratio2.40
Quick Ratio2.40
Debt to Market Cap0.00
Net Debt to EBITDA0.32
Interest Coverage Ratio-32.41
Taxes
In the past 12 months, Serina Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Serina Therapeutics EV to EBITDA ratio is -3.19, with an EV/FCF ratio of -1.95.
EV to Sales597.58
EV to EBITDA-3.19
EV to Free Cash Flow-1.95
EV to Operating Cash Flow-1.95
Balance Sheet
Serina Therapeutics has $6.04M in cash and marketable securities with $185.00K in debt, giving a net cash position of -$5.86M billion.
Cash & Marketable Securities$6.04M
Total Debt$185.00K
Net Cash-$5.86M
Net Cash Per Share-$0.57
Tangible Book Value Per Share$0.07
Margins
Gross margin is -99.23%, with operating margin of -30442.86%, and net profit margin of -19894.64%.
Gross Margin-99.23%
Operating Margin-30442.86%
Pretax Margin-19894.64%
Net Profit Margin-19894.64%
EBITDA Margin-18726.79%
EBIT Margin-19073.21%
Analyst Forecast
The average price target for Serina Therapeutics is $15.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$15.00
Price Target Upside181.95% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast34.04%
EPS Growth Forecast55.34%